Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address unmet medical needs in the United States, Europe and internationally.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared ...

Night - Clear. Winds from WSW to W at 7 to 9 mph (11.3 to 14.5 kph). The overnight low will be 43 °F (6.1 °C). Sunny with a high of 55 °F (12.8 °C). Winds W at 6 to 9 mph (9.7 to 14.5 kph ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the French drugmaker to replace Merdad Parsey, M.D ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere ...

Still, in the U.S. alone, Gilead has an eye on the 44% of people with HIV who have not achieved viral suppression through PrEP and set a goal of cranking up the U.S. PrEP market to encompass more ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Details are thin on the ground, but we know Gilead is tapping into Terray’s so-called tNova platform, the startup’s generative AI. This platform is designed to improve the speed, cost and ...

Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Berger succeeds Merdad ...